Projected Price to Earnings: Neurogene Corp (NGNE)
Neurogene Inc. (NGNE) specializes in developing gene therapies for the treatment of nervous system disorders. This daily price chart reflects a P/E ratio of 0.00. Positive investor sentiment is driven by successful interim tests for the treatment of Rett syndrome. The business model relies on high patent profitability, where primary costs are concentrated in research, while subsequent global rollout requires minimal investment.
NGNE (Neurogene Therapeutics): analytical breakdowns and indicator data
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Neurogene Inc.|NGNE - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Neurogene Inc.|NGNE - Company Cumulative Debt|Debt to Book Capitalization Ratio Neurogene Inc|NGNE - Company Long-Term Indebtedness|Company Short-Term Debts Neurogene|Quick Liquidity Indicator neurogene.com
- company profitability and valuation multiples indicators:
NGNE - Final Profit|Projected Future Earnings Neurogene Inc.|NGNE - Business Payback Period|Future Price to Earnings Neurogene Corp|NGNE - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Neurogene Inc|NGNE - Operating profit before deduction of amortization|Net earnings per share for the last 12 months Neurogene|NGNE - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months neurogene.com|NGNE - Earnings per share growth this year|Earnings growth forecast for next year Neurogene Inc.
- sales volume and revenue information:
Analysis of all company metrics:NGNE Neurogene
Neurogene Inc. (NGNE) creates high asset market value through complex R&D developments and patents in the field of gene therapy. Investors bake this potential into the forward P/E, calculated as the ratio of current market capitalization to expected net income. This metric reflects the market's willingness to pay a premium for future success in clinical trials. By analyzing changes in the company's forward price-to-earnings multiple, one can assess the stability of confidence in the commercialization of its drugs. A decline in this indicator signals rising risks of failing to achieve financial targets.
Who Neurogene Inc. competes with
Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Regencell - Projected Price to Earnings|Forward P/E Multiple Axsome Corp AXSM|ACAD - Future Price to Earnings|Future Price to Earnings Multiple XENE (xenon-pharma.com)|Viking Therapeutics, Inc. (VKTX) - Future Price to Earnings|Projected Price to Earnings Ratio Supernus Pharmaceuticals, Inc. (SUPN)|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|DNLI - Forward Price to Earnings Multiple|Forward P/E Multiple HRMY|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Price to Future Earnings Ratio|Praxis Medicines - Forward P/E Multiple|Projected Price to Earnings Ratio Anavex Life Sciences Corp|CBLL (CeriBell, Inc.) - Projected Price to Earnings|Prothena - Future Price to Earnings Multiple|ALEC (Alector Inc.) - Forward P/E Multiple|Annexon Biosciences (ANNX) - Market Cap to Projected Earnings|Future Price to Earnings Omeros Corporation (OMER)|AC Immune Inc - Price to Future Earnings Ratio|Forward P/E Multiple VYGR (Voyager Therapeutics)|NMRA - Projected Price to Earnings|SCLX: Projected Price to Earnings|Market Cap to Projected Earnings Tevogen Bio Holdings Inc. TVGN|alphacognition.com (ACOG) - Future Price to Earnings|Price to Future Earnings Ratio CGTX|IKT (Inhibikase Therapeutics) - Forward P/E Multiple|SAVA - Forward Price to Earnings Multiple|Future Price to Earnings Assertio Holdings, Inc. (ASRT)|coyatherapeutics.com - Price to Future Earnings Ratio|Forward P/E Multiple VTGN (Vistagen)|Ovid Therapeutics Inc (OVID) - Projected Price to Earnings Ratio|ABOS - Future Price to Earnings|CRVO (cervomed.com) - Price to Future Earnings Ratio|ATHE: Forward P/E Multiple|Projected Price to Earnings Ratio Clene (CLNN)|Projected Price to Earnings PEPG|Forward P/E Multiple Jupiter Neurosciences, Inc.|Future Price to Earnings Relmada Therapeutics (RLMD)|ANVS (annovisbio.com) - Future Price to Earnings Multiple|Future Price to Earnings Grace Therapeutics GRCE|Firefly Neuroscience, Inc. (AIFF) - Projected Price to Earnings Ratio|KLTO - Future Price to Earnings|NRSN (NeuroSense Therapeutics) - Price to Future Earnings Ratio|RVPH: Forward P/E Multiple|Projected Price to Earnings Ratio MetaVia (MTVA)|Projected Price to Earnings NRXS|Forward P/E Multiple Helius Medical Technologies Inc.|Future Price to Earnings Passage Bio, Inc. (PASG)|NEUP (bionomics.com.au) - Future Price to Earnings Multiple|Future Price to Earnings Minerva Neurosciences NERV|athira.com (ATHA) - Projected Price to Earnings Ratio|Addex Therapeutics Ltd - Forward P/E Multiple|Forward Price to Earnings Multiple Alzamend Neuro, Inc. (ALZN)|CYCN: Forward P/E Multiple|Projected Price to Earnings Ratio Protagenic Therapeutics, Inc. (PTIX)|Future Price to Earnings Pasithea Therapeutics Corp|Price to Future Earnings Ratio CRGT (Cortigent Medical)|Forward P/E Multiple ATXI|BCLI - Projected Price to Earnings Ratio|Cara Therapeutics, Inc - Projected Price to Earnings|Future Price to Earnings Multiple CHRO|Eliem - Forward P/E Multiple|Market Cap to Projected Earnings Intra-Cellular Therapies ITCI|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|Price to Future Earnings Ratio MRNS|NKGN (NKGen) - Forward P/E Multiple|Projected Price to Earnings NeuroBo Pharma (NRBO)|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings synaptogen.com|Future Price to Earnings Trevena TRVN|VIGL: Price to Future Earnings Ratio|Anew Medical - Forward P/E Multiple|Forward Price to Earnings Multiple Cerevel Corp (CERE)
